CytoDyn Inc (CYDY)

Add to Watchlists
Create an Alert
0.5003 -0.01  -2.67% OTC Markets Feb 19, 20:00 Delayed 15m USD
View Full Chart
CYDY Price Chart
View All Performance Charts

CYDY Total Returns Comparison

Advertisement

CYDY One Page Reports

Edit

Profile

  • URL: http://www.cytodyn.com
  • Investor Relations URL: N/A
  • HQ State/Province: Washington
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: N/A
  • Next Earnings Release: N/A
  • Last Earnings Release: N/A
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: CytoDyn Inc is US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called as entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes on exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

CYDY Comparables

Edit

CYDY Excel Add-In Codes

  • Name: =YCI("CYDY","name")
  • Description: =YCI("CYDY","description")
  • Sector: =YCI("CYDY","sector")
  • Industry: =YCI("CYDY","industry")
  • Est. Current Fiscal Year End: =YCI("CYDY","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.